Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

The RxPONDER and TAILORx trials demonstrated benefit from adjuvant chemotherapy in patients age ≤ 50 with node-positive breast cancer and Recurrence Score (RS) 0–26, and in node-negative disease with RS 16–25, respectively, but no benefit in older women with the same clinical features. We analyzed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Qing, Tao, Karn, Thomas, Rozenblit, Mariya, Foldi, Julia, Marczyk, Michal, Shan, Naing Lin, Blenman, Kim, Holtrich, Uwe, Kalinsky, Kevin, Meric-Bernstam, Funda, Pusztai, Lajos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640562/
https://www.ncbi.nlm.nih.gov/pubmed/36344517
http://dx.doi.org/10.1038/s41523-022-00492-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640562/
https://www.ncbi.nlm.nih.gov/pubmed/36344517
http://dx.doi.org/10.1038/s41523-022-00492-0

Ejemplares similares